Given the important role of ACE2 in the process of myocardial infection, a possible strategy for COVID-19 therapy might be to inhibit the expression of ACE2 in cardiomyocytes using the recently reported miR-200c, BRD2 inhibitors, and BET inhibitors [88-90]. Here, ACE2 is linked to COVID-19.